PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 22534775-7 2012 However, the assay with the addition of exogenous antithrombin detected falsely high concentrations of rivaroxaban even in plasma samples from controls who had not taken rivaroxaban (intercept values using the high calibrator set and the low calibrator set: +26.49 ng/ml and +13.71 ng/ml, respectively). Rivaroxaban 103-114 serpin family C member 1 Homo sapiens 50-62 25869030-0 2015 Successful treatment with rivaroxaban of an extended superficial vein thrombosis in a patient with acquired antithrombin deficiency due to Peg-asparaginase treatment. Rivaroxaban 26-37 serpin family C member 1 Homo sapiens 108-120 32039550-6 2020 RESULTS: Our data confirmed the overestimation of apixaban and rivaroxaban levels by the antithrombin-supplemented anti-Xa method (Berichrom). Rivaroxaban 63-74 serpin family C member 1 Homo sapiens 89-101 21655672-8 2011 The AT assay dependent on thrombin activity was not influenced by rivaroxaban, whereas the AT levels dependent on factor Xa activity were significantly increased by rivaroxaban. Rivaroxaban 165-176 serpin family C member 1 Homo sapiens 91-93 20946166-4 2011 MATERIALS AND METHODS: Rivaroxaban was added to plasma from healthy subjects in the concentration range 0-1000 mug L(-1) and analyzed using different reagents for activated partial thromboplastin time (APTT), prothrombin time (PT), antithrombin, fibrinogen and activated protein C (APC) resistance assays. Rivaroxaban 23-34 serpin family C member 1 Homo sapiens 232-244 19170587-4 2009 Rivaroxaban is a small molecule directed at active sites, and the agent mechanistically differs from traditional anticoagulants, such as heparins and fondaparinux, in that its activity is independent of antithrombin and its ability to inhibit prothrombinase bound factor Xa. Rivaroxaban 0-11 serpin family C member 1 Homo sapiens 203-215 29526957-6 2018 Rivaroxaban (15 mg) was continued for 6 months with no recurrence, indicating the efficacy of this factor Xa inhibitor for the treatment and prevention of VTE in patients with antithrombin deficiency. Rivaroxaban 0-11 serpin family C member 1 Homo sapiens 176-188 28888219-10 2018 CONCLUSIONS: Residual plasma rivaroxaban at the trough steady state may explain the antithrombin effect of rivaroxaban in patients with nonvalvular atrial fibrillation. Rivaroxaban 29-40 serpin family C member 1 Homo sapiens 84-96 28888219-10 2018 CONCLUSIONS: Residual plasma rivaroxaban at the trough steady state may explain the antithrombin effect of rivaroxaban in patients with nonvalvular atrial fibrillation. Rivaroxaban 107-118 serpin family C member 1 Homo sapiens 84-96 30279820-8 2017 The present case suggests that rivaroxaban is a direct Factor Xa inhibitor and does not require cofactors such as antithrombin-III, thus it is suitable for anticoagulation therapy in patients with low antithrombin-III activity.>. Rivaroxaban 31-42 serpin family C member 1 Homo sapiens 201-217 28794370-5 2017 The present case illustrates the effectiveness of rivaroxaban in preventing thromboembolisms due to surgery, even in very elderly patients with antithrombin deficiency. Rivaroxaban 50-61 serpin family C member 1 Homo sapiens 144-156